Currently out of the existing stock ratings of Adnan Butt, 50 are a BUY (86.21%), 2 are a HOLD (3.45%), 6 are a SELL (10.34%).

Adnan Butt

Work Performance Price Targets & Ratings Chart

Analyst Adnan Butt, carries an average stock price target met ratio of 79.26% that have a potential upside of 88.79% achieved within 512 days. Previously, Adnan Butt worked at GUGGENHEIM, RBC.

Adnan Butt’s has documented 103 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 21-Feb-2019.

Wall Street Analyst Adnan Butt

Analyst best performing recommendations are on ITCI (INTRACELLULAR TH).
The best stock recommendation documented was for ITCI (INTRACELLULAR TH) at 9/16/2015. The price target of $42 was fulfilled within 9 days with a profit of $6.79 (13.92%) receiving and performance score of 15.46.

Average potential price target upside

of $59.67 (13.22%) on REGN (REGENERON PHARMACEUTICALS).
of $34.87 (249.7%) on ITCI (INTRACELLULAR TH).
of $21.49 (112.59%) on AERI (AERIE PHARMACEUTICALS).

MDCO The Medicines Company MNKD MannKind Corp OCUL Ocular Therapeutix REGN Regeneron Pharmaceuticals SPPI Spectrum Pharmaceuticals AERI Aerie Pharmaceuticals ITCI Intracellular Th SGEN Seagen NBRV Nabriva Therapeutics AG

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gbola Amusa (CHARDAN CAPITAL)